相关实验视频
Updated: Jul 18, 2025
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.5K
非侵袭性皮肤过渡感应模式刺激疗法 提供动作震 缓解帕金森病的症状
Salima Brillman1, Pravin Khemani2, Stuart H Isaacson3
1Parkinson's Disease and Movement Disorders Center of Silicon Valley, Palo Alto, CA, US.
Tremor and other hyperkinetic movements (New York, N.Y.)
|August 28, 2023
概括
通过皮肤进行 afferent 模式刺激 (TAPS) 显著减少了帕金森病 (PD) 患者的动作震. 这种非侵入性治疗为PD患者改善日常活动提供了一个有希望的新治疗选择.
科学领域:
- 神经学 神经学
- 生物医学工程 生物医学工程
- 神经外科 神经外科
背景情况:
- 帕金森病 (PD) 通常会导致动作震,影响日常生活.
- 穿皮 afferent 模式刺激 (TAPS) 是一种非侵入性神经调节技术,针对产生震的大脑区域.
- 之前的研究主要集中在TAPS治疗基本震 (ET) 上;其在PD中的有效性不太清楚.
研究的目的:
- 评估TAPS在缓解帕金森病诊断患者动作震方面的有效性.
- 评估TAPS对客观震测量和患者报告的功能结果的影响.
主要方法:
- 一项前性开放性研究涉及40名患有动作震的PD患者.
- 参与者接受了为期四周的在家TAPS,与远程医疗检查.
- 震动强度,MDS-UPDRS III和BF-ADL得分是主要和次要结果措施.
主要成果:
- TAPS显示震强度的中位数减少了64% (p < 0.001),其中79%实现了≥50%的减少.
- 在MDS-UPDRS III震评级和BF-ADL分数中观察到显著的改善.
- 很高比例的患者 (75-83%) 和临床医生 (78-83%) 报告有意义的改善.
结论:
- 在帕金森病患者中,TAPS为动作震提供了临床显著的缓解.
- 该疗法耐受性良好,有轻微的不良事件,如皮肤刺激.
- TAPS代表了一种可行的,非侵入性的治疗选择,用于管理PD相关的震.
相关概念视频
01:24Parkinson's Disease: Treatment
295
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295
01:15Parkinson's Disease: Overview
593
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
593